Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a condition that attacks your nerves. ... No. Life expectancy with CIDP is the same as it is without the disease. Is CIDP a form of MS?

“Dosing the first patient in our Phase 2 CIDP trial marks an important step forward in our mission to deliver targeted, mechanism-based immunomodulation for patients with autoimmune diseases ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...

Physicians from Bochum have used a cancer treatment method to treat severe autoimmune diseases.

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the ...

DataM Intelligence | competitive Intelligence CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patient ...

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...